Free Cash Flow Chart

View Free Cash Flow for LXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow Chart
Start Trial

Historical Free Cash Flow Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -64.99M
March 31, 2026 -38.80M
December 31, 2025 -67.85M
September 30, 2025 -73.89M
June 30, 2025 -103.98M
March 31, 2025 -169.77M
December 31, 2024 -181.12M
September 30, 2024 -208.39M
June 30, 2024 -196.17M
March 31, 2024 -185.64M
December 31, 2023 -162.37M
September 30, 2023 -134.63M
June 30, 2023 -112.38M
March 31, 2023 -98.54M
December 31, 2022 -90.18M
September 30, 2022 -90.21M
June 30, 2022 -88.13M
March 31, 2022 -86.54M
December 31, 2021 -88.24M
September 30, 2021 -99.68M
June 30, 2021 -122.73M
March 31, 2021 -146.20M
December 31, 2020 -143.06M
September 30, 2020 -133.13M
June 30, 2020 97.98M
Date Value
March 31, 2020 117.37M
December 31, 2019 113.74M
September 30, 2019 110.94M
June 30, 2019 -101.94M
March 31, 2019 -127.58M
December 31, 2018 -148.70M
September 30, 2018 -155.25M
June 30, 2018 -167.09M
March 31, 2018 -146.85M
December 31, 2017 -185.62M
September 30, 2017 -200.85M
June 30, 2017 -202.06M
March 31, 2017 -217.65M
December 31, 2016 -175.86M
September 30, 2016 138.76M
June 30, 2016 148.32M
March 31, 2016 163.57M
December 31, 2015 183.87M
September 30, 2015 -86.30M
June 30, 2015 -81.83M
March 31, 2015 -68.86M
December 31, 2014 -75.70M
September 30, 2014 -93.17M
June 30, 2014 -96.17M
March 31, 2014 -98.04M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Viatris, Inc. 1.806B
Pfizer Inc. 10.99B
ANI Pharmaceuticals, Inc. 167.52M
Corcept Therapeutics, Inc. 106.92M
Veru, Inc. -26.04M